Last reviewed · How we verify
placebo tablets
Placebo tablets produce therapeutic effects through the placebo effect, wherein the expectation of treatment triggers physiological and psychological responses independent of active pharmacological ingredients.
Placebo tablets produce therapeutic effects through the placebo effect, wherein the expectation of treatment triggers physiological and psychological responses independent of active pharmacological ingredients. Used for Research and clinical trial control comparator (not a therapeutic indication).
At a glance
| Generic name | placebo tablets |
|---|---|
| Also known as | 2g of intravenous ceftriaxone or one β-lactam/β-lactamase combination(dose adjusted according to renal clearance) or 400mg of intravenous moxifloxacin, Placebo Placebo, Placebo, Suger pills, Juyuansuanjia Huanshi Pian |
| Sponsor | Wake Forest University Health Sciences |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebo tablets contain no active pharmaceutical ingredients but can elicit measurable clinical improvements through patient expectation, conditioning, and activation of endogenous healing mechanisms. The placebo effect involves both psychological factors (belief and expectation) and neurobiological pathways (e.g., endogenous opioid release, dopamine signaling). This phenomenon is particularly effective for subjective symptoms such as pain, nausea, and fatigue.
Approved indications
- Research and clinical trial control comparator (not a therapeutic indication)
Common side effects
- Nocebo effects (adverse events attributed to placebo)
Key clinical trials
- A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP) (PHASE2)
- Trial of Suvorexant for Sleep in Children With Autism (PHASE2)
- The Effect of NP-2006 on Sleep Quality and Health (NA)
- Adenosine 2A Receptor Antagonism and AIH in ALS (PHASE1, PHASE2)
- Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC) (PHASE2, PHASE3)
- The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists (PHASE1)
- Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID (PHASE3)
- A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- placebo tablets CI brief — competitive landscape report
- placebo tablets updates RSS · CI watch RSS
- Wake Forest University Health Sciences portfolio CI